中國生命集團(08296.HK)擬不超1080萬元收購廣東因微約19.46%股權
格隆匯7月29日丨中國生命集團(08296.HK)公吿,於2024年7月29日,公司及中科訊達(公司間接全資附屬公司)與南嶽資產訂立股權轉讓協議。根據股權轉讓協議,公司及中科訊達有條件同意向南嶽資產收購南嶽資產出資廣東因微繳足股本(相當於廣東因微約19.46%股權),最高代價為人民幣1080萬元,將透過根據特別授權向南嶽資產或其代名人發行可換股債券方式償付。於股權轉讓協議完成後,中科訊達將持有廣東因微約19.46%股權。
廣東因微主要從事生物芯片研發、高通量測序、大數據雲計算分析及個性化醫療諮詢服務。其為國內外醫療機構、體檢機構、科研機構、製藥公司等提供用於生物研究及臨牀診斷的生物芯片,並提供相關服務。
集團一直積極尋求多元化其收入來源,以提升股東回報。集團已形成傳統殯葬服務、新興生物科技為主業務格局。集團自2019年初起涉足生物科技業務。
廣東因微於2015年由中國頂級生物物理機構的專業科學家團隊創立。廣東因微主要從事生物芯片研發、高通量測序、大數據雲計算分析及個性化醫療諮詢服務。近年來,廣東因微在腫瘤、心腦血管疾病、糖尿病、神經系統等多種疾病檢測生物芯片研發方面取得巨大成功。董事認為,收購事項可進一步提升集團在生物科技行業的科研實力及創新能力,以及豐富集團的產品線,併為集團現有業務帶來協同效益。預計實現廣東因微的生物芯片產品銷售後可落實本公司的投資回報及改善集團的財務表現,旨在實現股東回報最大化。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.